PL2852671T3 - Wytwarzanie ludzkich komórek ips z użyciem syntetycznego samoreplikującego się rna - Google Patents

Wytwarzanie ludzkich komórek ips z użyciem syntetycznego samoreplikującego się rna

Info

Publication number
PL2852671T3
PL2852671T3 PL13794196T PL13794196T PL2852671T3 PL 2852671 T3 PL2852671 T3 PL 2852671T3 PL 13794196 T PL13794196 T PL 13794196T PL 13794196 T PL13794196 T PL 13794196T PL 2852671 T3 PL2852671 T3 PL 2852671T3
Authority
PL
Poland
Prior art keywords
selfplicating
rna
synthetic
manufacture
ips cells
Prior art date
Application number
PL13794196T
Other languages
English (en)
Inventor
Steven F. Dowdy
Naohisa YOSHIOKA
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of PL2852671T3 publication Critical patent/PL2852671T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Prostheses (AREA)
PL13794196T 2012-05-21 2013-05-21 Wytwarzanie ludzkich komórek ips z użyciem syntetycznego samoreplikującego się rna PL2852671T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261649876P 2012-05-21 2012-05-21
US201361798229P 2013-03-15 2013-03-15
PCT/US2013/041980 WO2013177133A2 (en) 2012-05-21 2013-05-21 Generation of human ips cells by a synthetic self- replicative rna
EP13794196.9A EP2852671B1 (en) 2012-05-21 2013-05-21 Generation of human ips cells by a synthetic self- replicative rna

Publications (1)

Publication Number Publication Date
PL2852671T3 true PL2852671T3 (pl) 2019-06-28

Family

ID=49624495

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13794196T PL2852671T3 (pl) 2012-05-21 2013-05-21 Wytwarzanie ludzkich komórek ips z użyciem syntetycznego samoreplikującego się rna

Country Status (14)

Country Link
US (4) US9862930B2 (pl)
EP (1) EP2852671B1 (pl)
JP (1) JP6396893B2 (pl)
CN (1) CN104508131B (pl)
AU (1) AU2013266496B2 (pl)
CA (2) CA2873964C (pl)
DK (1) DK2852671T3 (pl)
ES (1) ES2698527T3 (pl)
HU (1) HUE041853T2 (pl)
IL (2) IL235628B (pl)
PL (1) PL2852671T3 (pl)
PT (1) PT2852671T (pl)
SG (1) SG11201407595UA (pl)
WO (1) WO2013177133A2 (pl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3169310A1 (en) 2014-07-15 2017-05-24 Life Technologies Corporation Compositions with lipid aggregates and methods for efficient delivery of molecules to cells
AU2016355191B2 (en) * 2015-11-18 2023-06-29 Orbis Health Solutions Llc T7 alpha viral vector system
MX391337B (es) 2016-04-13 2025-03-21 Janssen Pharmaceuticals Inc Star Sistemas de replicón de arterivirus recombinantes y usos de estos.
US20200385687A1 (en) * 2017-02-24 2020-12-10 Koji Tanabe Production method for artificial pluripotent stem cells
EP3587563A4 (en) * 2017-02-24 2021-01-06 Koji Tanabe NERVOUS CELL PRODUCTION PROCESS
CA3068917A1 (en) * 2017-07-05 2019-01-10 Wisconsin Alumni Research Foundation Mineral coated microparticles for co-delivery of anti-inflammatory molecules with nucleic acids to improve gene delivery outcomes
AU2018333503B2 (en) * 2017-09-13 2025-03-27 BioNTech SE RNA replicon for reprogramming somatic cells
US11229699B2 (en) 2017-11-06 2022-01-25 Intervet Inc. Feline calicivirus vaccine
WO2019107354A1 (ja) * 2017-11-30 2019-06-06 アイ ピース， インコーポレイテッド 神経系細胞の作製方法
KR102143320B1 (ko) * 2018-08-28 2020-08-12 주식회사 스템랩 합성 메신저 rna를 이용하여 소변세포를 신경줄기세포로 직접 역분화하는 방법
US12274733B2 (en) 2018-09-28 2025-04-15 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
AU2019347666B2 (en) 2018-09-28 2025-10-02 President And Fellows Of Harvard College Cellular reprogramming to reverse aging and promote organ and tissue regeneration
EP3864027A1 (en) * 2018-10-08 2021-08-18 Janssen Pharmaceuticals, Inc. Alphavirus-based replicons for administration of biotherapeutics
US12286646B2 (en) 2019-01-10 2025-04-29 Massachusetts Institute Of Technology Methods for in vitro evolution of constructs derived from viruses
WO2020264138A1 (en) * 2019-06-27 2020-12-30 Emd Millipore Corporation Cell expansion with self-replicating rna vectors expressing immortalization proteins
KR102249776B1 (ko) * 2019-11-25 2021-05-10 연세대학교 산학협력단 개선된 생체 내 리프로그래밍 시스템 및 이를 이용한 세포 전환 방법
IL294290A (en) 2019-12-31 2022-08-01 Elixirgen Therapeutics Inc Transient temperature-based delivery of nucleic acids and proteins to cells and tissues
EP4119166A4 (en) 2020-03-12 2024-06-05 Institute for Basic Science Composition for inducing apoptosis of cells having genomic sequence variation and method for inducing apoptosis of cells by using composition
CN116018402A (zh) * 2020-09-04 2023-04-25 心脏康复株式会社 iPS细胞的品质改善剂、iPS细胞的制备方法、iPS细胞、及iPS细胞制备用组合物
CN112458064A (zh) * 2020-11-20 2021-03-09 广西大学 盖他病毒全长感染性克隆、复制子系统及其制备和应用
CN112852841A (zh) * 2021-02-03 2021-05-28 郑州大学 一种高效表达目的蛋白的顺式复制子rna构建体
CN117083374A (zh) 2021-03-25 2023-11-17 蓝岩治疗有限公司 获得诱导多能干细胞的方法
AU2022269877A1 (en) * 2021-05-04 2023-12-21 Mogrify Limited Cell conversion
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
WO2023288287A2 (en) * 2021-07-15 2023-01-19 Turn Biotechnologies, Inc. Synthetic, persistent rna constructs and methods of use for cell rejuvenation and for treatment
WO2023288288A1 (en) * 2021-07-15 2023-01-19 Turn Biotechnologies, Inc. Synthetic, persistent rna constructs with on/off mechanism for controlled expression and methods of use
WO2023288285A1 (en) * 2021-07-15 2023-01-19 Turn Biotechnologies, Inc. Polycistronic expression vectors
EP4453205A4 (en) * 2021-12-20 2025-12-17 Elevatebio Tech Inc COMPOSITIONS AND METHODS FOR CELLULAR REPROGRAMMING WITH CIRCULAR RNA
KR20250005159A (ko) 2022-04-28 2025-01-09 블루록 테라퓨틱스 엘피 안전한 게놈 통합을 위한 신규한 부위 및 그의 사용 방법
CN119998259A (zh) 2022-06-23 2025-05-13 特恩生物技术公司 脂质结构及包含其的组合物
AU2023398007A1 (en) 2022-12-13 2025-06-19 Bayer Aktiengesellschaft Engineered type v rna programmable endonucleases and their uses
US12252518B2 (en) 2023-01-06 2025-03-18 Life Biosciences, Inc. Methods of treating non-arteritic anterior ischemic optic neuropathy
TW202449160A (zh) 2023-02-06 2024-12-16 美商藍岩醫療公司 降解決定子(degron)融合蛋白及其生產及使用方法
WO2025076291A1 (en) 2023-10-06 2025-04-10 Bluerock Therapeutics Lp Engineered type v rna programmable endonucleases and their uses
WO2025166063A1 (en) 2024-01-31 2025-08-07 Bluerock Therapeutics Lp Igfbp2 in cell culture
WO2025207481A1 (en) 2024-03-25 2025-10-02 Bluerock Therapeutics Lp Measuring viability in cell aggregates
WO2026006245A1 (en) 2024-06-25 2026-01-02 Bluerock Therapeutics Lp Three-dimensional culturing of pluripotent stem cells for improved differentiability

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
CA2097708A1 (en) 1990-12-06 1992-06-07 Stephen P. A. Fodor Very large scale immobilized polymer synthesis
WO1997038087A2 (en) 1996-04-05 1997-10-16 Chiron Corporation Alphaviral vector with reduced inhibition of cellular macromolecular synthesis
US5811407A (en) 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
US20030232324A1 (en) * 2001-05-31 2003-12-18 Chiron Corporation Chimeric alphavirus replicon particles
ES2330202T5 (es) 2001-09-06 2014-01-20 Alphavax, Inc. Sistemas vectores basados en replicones de alfavirus
EP1386926A1 (en) 2002-07-29 2004-02-04 Bioxtal Methods for producing labelled recombinant polypeptides and uses thereof
US20050271639A1 (en) * 2002-08-22 2005-12-08 Penn Marc S Genetically engineered cells for therapeutic applications
DK3246399T3 (da) 2002-12-13 2021-10-04 Alphavax Inc Alfavirus-partikler og fremgangsmåder til fremstilling
MXPA05010007A (es) 2003-03-20 2006-03-10 Alphavax Inc Replicones de alfavirus y construcciones auxiliares mejorados.
US20060198854A1 (en) 2004-12-28 2006-09-07 Peter Pushko Vector platforms derived from the alphavirus vaccines
WO2009067563A1 (en) 2007-11-19 2009-05-28 The Regents Of The University Of California Generation of pluripotent cells from fibroblasts
EP2072618A1 (en) 2007-12-14 2009-06-24 Johannes Gutenberg-Universität Mainz Use of RNA for reprogramming somatic cells
GB0801215D0 (en) * 2008-01-23 2008-02-27 Univ Sheffield Cell re-programming
US20110061118A1 (en) * 2008-03-17 2011-03-10 Helmholtz Zentrum Munchen Vectors and methods for generating vector-free induced pluripotent stem (ips) cells using site-specific recombination
EP3231869A1 (en) * 2008-06-13 2017-10-18 Whitehead Institute for Biomedical Research Programming and reprogramming of cells
WO2010028019A2 (en) 2008-09-03 2010-03-11 The General Hospital Corporation Direct reprogramming of somatic cells using non-integrating vectors
KR101764100B1 (ko) 2009-02-27 2017-08-02 고쿠리츠 다이가쿠 호진 교토 다이가쿠 신규한 핵 재프로그래밍 물질
ES2540958T3 (es) * 2009-04-08 2015-07-15 Alphavax, Inc. Partículas de replicón de alfavirus que expresan TRP2
CN102395672A (zh) 2009-04-13 2012-03-28 加利福尼亚大学董事会 用于干细胞培养的方法和组合物
US20130196865A1 (en) * 2010-03-03 2013-08-01 The General Hospital Corporation Method for selecting an ips cell
EP3072961A1 (en) * 2010-04-16 2016-09-28 Children's Medical Center Corporation Sustained polypeptide expression from synthetic, modified rnas and uses thereof
CA2890529C (en) 2012-11-09 2020-07-28 Biontech Ag Method for modification of cellular rna expression comprising interferon (ifn) receptors and signalling

Also Published As

Publication number Publication date
AU2013266496A1 (en) 2014-11-27
ES2698527T3 (es) 2019-02-05
HUE041853T2 (hu) 2019-05-28
US10370646B2 (en) 2019-08-06
DK2852671T3 (en) 2018-12-10
US20150159143A1 (en) 2015-06-11
SG11201407595UA (en) 2014-12-30
CN104508131B (zh) 2018-11-23
WO2013177133A3 (en) 2014-03-20
IL235628A0 (en) 2015-01-29
US10793833B2 (en) 2020-10-06
US20210108179A1 (en) 2021-04-15
CN104508131A (zh) 2015-04-08
CA3279208A1 (en) 2025-10-30
CA2873964C (en) 2025-09-16
JP2015519898A (ja) 2015-07-16
IL235628B (en) 2020-03-31
US20190338252A1 (en) 2019-11-07
US9862930B2 (en) 2018-01-09
JP6396893B2 (ja) 2018-09-26
PT2852671T (pt) 2018-11-29
US20180216079A1 (en) 2018-08-02
AU2013266496B2 (en) 2018-08-09
WO2013177133A2 (en) 2013-11-28
EP2852671A2 (en) 2015-04-01
CA2873964A1 (en) 2013-11-28
IL272917A (en) 2020-04-30
EP2852671B1 (en) 2018-08-22
EP2852671A4 (en) 2015-12-23

Similar Documents

Publication Publication Date Title
PL2852671T3 (pl) Wytwarzanie ludzkich komórek ips z użyciem syntetycznego samoreplikującego się rna
IL284998A (en) Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
IL237592B (en) Methods of expanding and assessing b cells and using expanded b cells to treat disease
IL229629B (en) Synthetic formulations and methods of manufacturing and using them
DK2863990T3 (da) Medicinsk mikroelektrode
LT2885010T (lt) Tautopatijos gydymo būdai
DK2900806T3 (da) Tredimensionel celledyrkning
EP2935546A4 (en) BIORAFFINATION OF RAW TALL OIL
LT3091141T (lt) Lengvesnės grindų plokštės iš mažiau medžiagų
BR112014007029A2 (pt) métodos aperfeiçoados de terapia gênica
EP2832328A4 (en) DISPOSABLE UNDERWEAR
EP2832327A4 (en) DISPOSABLE UNDERWEAR
HRP20181599T1 (hr) Proizvodnja i upotreba bakterijskog histamina
BR112014015814A8 (pt) fralda descartável
EP2821053A4 (en) CLEANSING COMPOSITION FOR THE SKIN
IL227732A0 (en) Cosmetic use
BR112014012223A2 (pt) fralda descartável
EP2889368A4 (en) PROTEIN PRODUCTION ACCELERATOR
BR112014026553A2 (pt) Fralda descartável
EP2810665A4 (en) bio-implant
HRP20182057T1 (hr) Temperaturno stabilni vodeni pripravci klokintocet-meksila
IL238545A0 (en) Plants for production of therapeutic proteins
BR112014012225A2 (pt) fralda descartável
IL259184A (en) Crystal of flumioxazin
EP2849764A4 (en) TRACE ELEMENT SOLUTION